Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,090Revenue $M8.4Net Margin (%)-1,796.4Z-Score-2.8
Enterprise Value $M2,575EPS $-1.5Operating Margin %-911.2F-Score4
P/E(ttm))0Cash Flow Per Share $-1.3Pre-tax Margin (%)-1,333.5Higher ROA y-yY
Price/Book010-y EBITDA Growth Rate %-29.0Quick Ratio18.3Cash flow > EarningsY
Price/Sales2245-y EBITDA Growth Rate %-38.1Current Ratio18.3Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-28.4Higher Current Ratio y-yY
Dividend Yield %4.2Insider Buy (3m)1ROE % (ttm)-444.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M117ROI % (ttm)-32.8Gross Margin Increase y-yN

Gurus Latest Trades with THRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
THRXSeth Klarman 2014-09-30 Reduce-0.28%$17.53 - $30.4
($22.87)
$ 17.92-28%Reduce -2.84%19,815,983
THRXSeth Klarman 2014-06-30 Reduce-0.23%$21.154 - $30.1
($23.88)
$ 17.92-33%Reduce -1.50%20,395,056
THRXSeth Klarman 2014-03-31 Add0.42%$24.31 - $32.63
($29.32)
$ 17.92-64%Add 2.79%20,705,801
THRXSeth Klarman 2013-12-31 Add1.65%$27.19 - $32.81
($29.19)
$ 17.92-63%Add 8.83%20,144,301
THRXJean-Marie Eveillard 2013-12-31 Add0.03%$27.19 - $32.81
($29.19)
$ 17.92-63%Add 23.40%1,509,404
THRXSeth Klarman 2013-09-30 Add2.3%$28.86 - $34.36
($31.06)
$ 17.92-73%Add 11.92%18,510,371
THRXSeth Klarman 2013-06-30 Add2.85%$18.15 - $33.74
($26.83)
$ 17.92-50%Add 22.02%16,538,977
THRXJean-Marie Eveillard 2013-06-30 Add0.08%$18.15 - $33.74
($26.83)
$ 17.92-50%Add 139.14%1,109,620
THRXJean-Marie Eveillard 2012-06-30 Add0.01%$14.11 - $19.04
($16.72)
$ 17.927%Add 24.23%509,710
THRXSeth Klarman 2012-03-31 Add0.22%$13.21 - $16.28
($13.91)
$ 17.9222%Add 2.30%14,553,800
THRXJean-Marie Eveillard 2012-03-31 Add0.01%$13.21 - $16.28
($13.91)
$ 17.9222%Add 25.59%410,310
THRXJulian Robertson 2011-09-30 Sold Out -1.2512%$14.05 - $20.04
($16.74)
$ 17.927%Sold Out0
THRXSeth Klarman 2011-09-30 Add0.84%$14.05 - $20.04
($16.74)
$ 17.927%Add 9.76%14,225,961
THRXJean-Marie Eveillard 2011-06-30 Reduce-0.02%$17.07 - $23.13
($20)
$ 17.92-12%Reduce -33.79%326,710
THRXDavid Swensen 2011-03-31 Sold Out -6.58%$16.91 - $20.77
($18.79)
$ 17.92-5%Sold Out0
THRXJulian Robertson 2011-03-31 Reduce-0.35%$16.91 - $20.77
($18.79)
$ 17.92-5%Reduce -20.94%211,686
THRXJean-Marie Eveillard 2011-03-31 Add0.02%$16.91 - $20.77
($18.79)
$ 17.92-5%Add 51.02%493,410
THRXWilbur Ross 2011-03-31 Sold Out $16.91 - $20.77
($18.79)
$ 17.92-5%Sold Out0
THRXDavid Swensen 2010-12-31 Buy 6.58%$16.12 - $23.08
($18.83)
$ 17.92-5%New holding230,465
THRXWilbur Ross 2010-12-31 Buy 0.13%$16.12 - $23.08
($18.83)
$ 17.92-5%New holding45,219
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

THRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


THRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLC10% Owner 2015-03-02Buy92,674$18.06-0.78view
GLAXOSMITHKLINE PLC10% Owner 2014-11-04Buy832,456$15.3616.67view
LEE JUNNINGSr. VP, Technical Operations 2014-08-13Sell53,424$22.5-20.36view
Shafer Bradford JSr VP, Gen. Counsel, Secretary 2014-08-12Sell28,156$22.13-19.02view
GLAXOSMITHKLINE PLC10% Owner 2014-08-11Buy172,651$22.66-20.92view
GLAXOSMITHKLINE PLC10% Owner 2014-05-09Buy317,770$26.89-33.36view
Shafer Bradford JSr VP, Gen. Counsel, Secretary 2014-03-03Sell65,806$36.73-51.21view
Mammen MathaiSVP, Research & Early Clin Dev 2014-02-14Sell35,000$39.36-54.47view
GLAXOSMITHKLINE PLC10% Owner 2014-02-11Buy342,229$37.55-52.28view
GLAXOSMITHKLINE PLC10% Owner 2013-10-29Buy130,473$37.66-52.42view

Press Releases about THRX :

    Quarterly/Annual Reports about THRX:

    News about THRX:

    Articles On GuruFocus.com
    Seth Klarman's Trades During Q1 2015 Apr 20 2015 
    Richard Perry's Fourth-Quarter Transactions Had High Impact on Portfolio Feb 16 2015 
    Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX Dec 05 2014 
    Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung Function Compared to Tiotropium Oct 17 2014 
    Theravance, Inc. Appoints Eric d'Esparbes as Senior Vice President and Chief Financial Officer Oct 15 2014 
    Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
    Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
    Seth Klarman's Top 5 Second Quarter Holdings Aug 14 2013 
    Top Four from Baupost’s Seth Klarman Jul 18 2013 
    What Can We Earn If We Invest in the Top Five Holdings of the Baupost Group? May 29 2013 


    More From Other Websites
    Nasdaq stocks posting largest percentage decreases Apr 24 2015
    Theravance Biopharma to Present New Data Highlighting in vitro Potency of VIBATIV(R) (telavancin)... Apr 16 2015
    THERAVANCE INC Files SEC form 8-K, Other Events Apr 16 2015
    Theravance Biopharma to Present at the Needham Healthcare Conference Apr 07 2015
    Theravance Biopharma Announces New Employment Inducement Awards Apr 02 2015
    Pharmacyclics Begins Imbruvica Combination Cancer Study - Analyst Blog Apr 02 2015
    THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure Mar 31 2015
    Should Theravance (THRX) Be On Your Radar Now? - Tale of the Tape Mar 24 2015
    KB Home and Biogen are big market movers Mar 20 2015
    Theravance/Glaxo's Breo Ellipta Gets Mixed FDA Panel View - Analyst Blog Mar 20 2015
    THERAVANCE INC Files SEC form 8-K, Other Events Mar 20 2015
    FDA panel backs Glaxo inhaler for adults, not adolescents Mar 19 2015
    GSK and Theravance announce outcome of US FDA Advisory Committee on BREO® ELLIPTA® in asthma Mar 19 2015
    GSK and Theravance Announce Outcome of US FDA Advisory Committee on BREO(R) ELLIPTA(R) in Asthma Mar 19 2015
    FDA panel backs Glaxo asthma drug for adults, not adolescents Mar 19 2015
    Theravance Announces Trading in Common Stock Halted Mar 19 2015
    Pharmacyclics' Imbruvica Encourages in a Phase III Study - Analyst Blog Mar 17 2015
    THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure Mar 17 2015
    FDA staff finds no new safety problems with Glaxo's asthma drug Mar 17 2015
    Billionaire Seth Klarman’s Biotech Stock Picks Mar 15 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK